Medsa Group Limited - Accounts to registrar (filleted)

REGISTERED NUMBER: 05084053 (England and Wales)

UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

FOR

MEDSA GROUP LIMITED

Page

Company Information

1

Abridged Balance Sheet

2

Notes to the Financial Statements

4

DIRECTORS:

J R Salvage

J M Lee

D N Sharpe

SECRETARY:

J R Salvage

REGISTERED OFFICE:

Sandy Farm

The Sands

Farnham

Surrey

GU10 1PX

REGISTERED NUMBER:

05084053 (England and Wales)

FIXED ASSETS

Tangible assets

4

9,030

5,173

Investments

5

3,519,518

3,397,832

3,528,548

3,403,005

CURRENT ASSETS

Stocks

357,484

338,603

Debtors

2,472,232

2,518,224

Cash at bank and in hand

10

16

2,829,726

2,856,843

CREDITORS

Amounts falling due within one year

227,429

256,663

NET CURRENT ASSETS

2,602,297

2,600,180

TOTAL ASSETS LESS CURRENT
LIABILITIES

6,130,845

6,003,185

CREDITORS

Amounts falling due after more than one year

5,883,781

5,754,857

NET ASSETS

247,064

248,328

CAPITAL AND RESERVES

Called up share capital

100

Retained earnings

246,964

248,228

SHAREHOLDERS' FUNDS

247,064

248,328

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2025 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

(a)	ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b)

preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

All the members have consented to the preparation of an abridged Balance Sheet for the year ended 31 December 2025 in accordance with Section 444(2A) of the Companies Act 2006.

In accordance with Section 444 of the Companies Act 2006, the Statement of Income and Retained Earnings has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 12 August 2026 and were signed on its behalf by:

D N Sharpe - Director

1.	STATUTORY INFORMATION

Medsa Group Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2.	ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Related party exemption

The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.

Turnover

Turnover represents the sale of corporate solutions products and services, excluding value added tax, during the year.

Turnover is recognised as the right to consideration arises and adjustments are made for accrued and deferred income.

Tangible fixed assets

Tangible fixed assets are stated at cost or valuation less accumulated depreciation. Cost includes costs directly attributable to making the asset capable of operating as intended by management.

Depreciation is provided at the following annual rates in order to write off each asset its estimated useful life.

Plant and machinery

-

25% on reducing balance

Fixtures and fittings

-

25% on reducing balance

Computer equipment

-

33.33% on cost

Investments in associates

Investments in subsidiary and associate undertakings are recognised at cost less impairment.

Stocks

Stocks are stated at the lower of cost and estimated selling price, less costs to complete and sell. Cost includes all costs of purchase, including costs to bring stock to its present location and condition. Provision is made for damaged, obsolete and slow-moving stock where appropriate.

Financial instruments

The company enters into basic financial instruments, which result in the recognition of financial assets and liabilities. Financial instruments are recognised at amortised cost, except for investments in subsidiaries and associate undertakings, which are measured at cost less impairment. At the end of each reporting period financial instruments are assessed for evidence of impairment, and changes are recognised in profit or loss.

Taxation

Taxation for the year comprises current tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current tax represents the amount of tax payable or receivable in respect of the taxable profit (or loss) for the current or past reporting periods.

Consideration is given to whether deferred tax should be provided in respect of material timing differences which have not reversed at the balance sheet date. Deferred tax assets are only recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or future taxable profits.

Current tax assets and liabilities are not discounted and are recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Foreign currencies

Transactions denominated in foreign currencies are translated into sterling and recorded at the rate of exchange ruling at the date of the transaction. Balances at the year-end denominated in a foreign currency are translated into sterling at the rate of exchange ruling at the balance sheet date.

Pension costs and other post-retirement benefits

The company operates a defined contribution pension scheme. Contributions payable are charged to the profit and loss in the period to which they relate.

Hire purchase and leasing commitments

Rentals payable under operating leases are charged to the profit and loss account on a straight line basis over the period of the lease.

3.	EMPLOYEES AND DIRECTORS

The average number of employees during the year was 18 (2024 - 18 ) .

4.	TANGIBLE FIXED ASSETS

Totals

£

COST

At 1 January 2025

112,042

Additions

8,896

At 31 December 2025

120,938

DEPRECIATION

At 1 January 2025

106,869

Charge for year

5,039

At 31 December 2025

111,908

NET BOOK VALUE

At 31 December 2025

9,030

At 31 December 2024

5,173

5.	FIXED ASSET INVESTMENTS

Information on investments other than loans is as follows:

Totals

£

COST

At 1 January 2025

and 31 December 2025

2,040,245

NET BOOK VALUE

At 31 December 2025

2,040,245

At 31 December 2024

2,040,245

Information on loans is as follows:

Totals

£

At 1 January 2025

1,357,587

Additions

121,686

At 31 December 2025

1,479,273

6.	LEASING AGREEMENTS

Minimum lease payments under non-cancellable operating leases fall due as follows:

2025

2024

£

Within one year

61,333

63,818

Between one and five years

235,012

In more than five years

107,714

166,467

404,059

465,297

7.	SECURED DEBTS

The following secured debts are included within creditors:

2025

2024

£

Bank overdrafts

92,073

99,718

Debentures

2,808,185

2,669,185

Debenture loan interest

151,712

3,051,970

2,920,615

A charge over all the undertaking, property and assets of the company was created on 6 December 2011 by Lloyds TSB Bank plc to secure all moneys and liabilities due.

Floating charges have been raised over all the property or undertaking of the company by a director to secure all debenture loan balances and interest due from the company.

8.	DIRECTORS' ADVANCES, CREDITS AND GUARANTEES

As at 31 December 2025, a director had loaned the company £2,267,449 (2024 - £2,277,525). The loan attracted interest at 1% over the Bank of England base rate up until 31 December 2013 and the amount due is repayable upon demand. No interest was charged on the loan during the year ended 31 December 2025.

As at 31 December 2025, an amount of £656,435 (2024 - £656,435) was owed to a director with regard to accrued interest charges on his loan account. The amounts due are included within Directors' current accounts and Other creditors due after more than one year.

As at 31 December 2025, a director had debenture loans due from the company of £2,808,185 (2024 - £2,669,185). No interest was charged on the loans during the year ended 31 December 2025.

As at 31 December 2025, an amount of £151,712 (2024 - £151,712) was owed to a director with regard to accrued interest charges on his debenture loans.

The debenture loans due and associated interest charges are repayable upon demand however the director has agreed not to request the secured liabilities for a period of twelve months from the date of approval of the balance sheet in order to support the company's continued operation on a going concern basis. The amounts due are therefore included within Debentures and Other creditors due after more than one year.

9.	RELATED PARTY DISCLOSURES

During the year ended 31 December 2025, Medsa Group Limited entered into the following transactions with related undertakings:

Outstanding Balance

Management Charges

B/Fwd

C/Fwd

2024

2025

Maxstim UK

2,098,714

2,066,088

200,000

240,000

Maxstim Europe

9,986

12,944

-

Greased Lightning

1,357,587

1,479,273

200,000

135,000

Rotafix (Northern)

81,876

46,201

126,370

39,917

Rotafix

400

2,400

-

The Magic Molecule Company

91,185

92,530

-

Greenman Plant Care

68,066

68,451

-

Contamination Control

63,917

65,268

-

Medsa Research

20,240

21,609

-

Heath Research

9,472

1,550

-

3,801,443

3,856,314

526,370

414,917